Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Lowy Website

Douglas R. Lowy, M.D.

Selected Publications

1)  Schiller JT, Lowy DR.
Virus infection and human cancer: an overview.
Recent Results Cancer Res. 193: 1-10, 2014.
[Journal]
2)  Handisurya A, Day PM, Thompson CD, Buck CB, Pang YY, Lowy DR, Schiller JT.
Characterization of Mus musculus papillomavirus 1 infection in situ reveals an unusual pattern of late gene expression and capsid protein localization.
J. Virol. 87: 13214-25, 2013.
[Journal]
3)  Safaeian M, Kemp TJ, Pan DY, Porras C, Cecilia Rodriguez A, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, Gonzalez P, Penrose K, Lowy DR, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Pinto LA.
Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: Results from the Costa Rica Vaccine Trial.
Hum Vaccin Immunother. 9, 2013.
[Journal]
4)  Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, Herrero R, Kemp T, Shelton G, Quint W, van Doorn LJ, Hildesheim A, Pinto LA.
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.
Cancer Prev Res (Phila). 6: 1242-50, 2013.
[Journal]
5)  Day PM, Thompson CD, Schowalter RM, Lowy DR, Schiller JT.
Identification of a Role for the trans-Golgi Network in Human Papillomavirus 16 Pseudovirus Infection.
J. Virol. 87: 3862-70, 2013.
[Journal]
6)  Zimonjic DB, Chan LN, Tripathi V, Lu J, Kwon O, Popescu NC, Lowy DR, Tamanoi F.
In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells.
BMC Cancer. 13: 198, 2013.
[Journal]
7)  Jagu S, Kwak K, Schiller JT, Lowy DR, Kleanthous H, Kalnin K, Wang C, Wang H, Chow LT, Huh WK, Jaganathan KS, Chivukula SV, Roden RB.
Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.
J. Virol. 87: 6127-36, 2013.
[Journal]
8)  Lang Kuhs KA, Gonzalez P, Struijk L, Castro F, Hildesheim A, van Doorn LJ, Rodriguez AC, Schiffman M, Quint W, Lowy DR, Porras C, Delvecchio C, Katki HA, Jimenez S, Safaeian M, Schiller J, Solomon D, Wacholder S, Herrero R, Kreimer AR.
Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica.
J. Infect. Dis. 208: 1643-52, 2013.
[Journal]
9)  Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ, Wacholder S, Kreimer AR.
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.
PLoS ONE. 8: e68329, 2013.
[Journal]
10)  Wang D, Moothart DR, Lowy DR, Qian X.
The expression of glyceraldehyde-3-phosphate dehydrogenase associated cell cycle (GACC) genes correlates with cancer stage and poor survival in patients with solid tumors.
PLoS ONE. 8: e61262, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 5/8/2014.